Estamos no ar no !
Saiba mais
Lite Strategy Inc
Sobre: Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients. The company operates in the segments: Digital Asset Treasury Strategy and Development of Pharmaceutical Products.
Funcionários: 5
Notícias
Positivo
Neutro
Negativo
Sentimento
3 meses
Positivo
0%
Neutro
100%
Negativo
0%
Gráficos de preços implementados com Lightweight Charts™